Studies have shown that lapatinib, an ErbB inhibitor, can prevent the downstream of ErbBs (p38 MAPK, MEK/ERK, and Akt/mTOR), the production of proinflammatory cytokines, and the activation of epithelial barrier injury-related pathways in severe acute respiratory syndrome coronavirus 2-induced non-infectious acute lung injury and fibrosis [27]. Here, EGFR is linked to acute lung injury.